Reference:
  1. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol 2020; 135:1492.
  2. Yang, Y; Le Ray, I; Zhu, J; et al.Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China.[J].JAMA Netw Open.2021,4(5):e218401.
  3. Burton GJ, Redman CW, Roberts JM, et al. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366: l2381.
  4. Poon LC, Galindo A, Surbek D, Chantraine F, Stepan H, Hyett J, Tan KH, Verlohren S. From first-trimester screening to risk stratification of evolving pre-eclampsia in second and third trimesters of pregnancy: comprehensive approach. Ultrasound Obstet Gynecol. 2020 Jan;55(1):5-12.
  5. Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase–specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014 Feb;63(2):346-52.
  6. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1: PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13-22.
  7. Bian X, Biswas A, Huang X, et al. Short-term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble sms-Like Tyrosin Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia. Hypertension. 2019, 74(1): 164-172.
  8. Brown MA, Magee LA, Kenny LC, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension 2018; 72:24.
  9. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre‐Eclampsia: Pathogenesis, Novel Diagnostics and Therapies. Nat Rev Nephrol. 2019, 15, 275–289.
  10. Sisti G, Colombi I. New blood pressure cut off for preeclampsia definition: 130/80 mmHg. Eur J Obstet Gynecol Reprod Biol 2019; 240:322. [11]Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, Shennan AH, Chappell LC; PARROT trial group. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019 May 4;393(10183):1807-1818. [12]Dreige, LA; Perschel, FH; Stütz, N; et al.Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study.[J].Hypertension.2021,77(2):461-471. [13]Ng QJ, Han JY, Saffari SE, et al. Longitudinal circulating placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1) concentrations during pregnancy in Asian women: a prospective cohort study. BMJ Open. 2019;9(5):e028321. [14]Semir Kose, Gamze Tuna, Gülnar Nuriyeva, Sabahattin Altunyurt, Gü Hüray Islekel, Omer Erbil Doğan. A prospective cohort study on the prediction of the diagnosis-to-delivery time in preeclamptic pregnancies: should the sFlt-1/PlGF ratio be added to routine evaluations? [J] Arch Gynecol Obstet. 2018;298(5):911-920. [15]Luke B, Brown MB, Eisenberg ML, et al. In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters. Am J Obstet Gynecol 2020; 222:350.e1. [16]Perales A, Delgado JL, de la Calle M, et al. sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain). Ultrasound Obstet Gynecol. 2017;50(3):373-382. [17]Suzuki H, Hirashima C, Nagayama S, Takahashi K, Yamamoto T, Matsubara S, Ohkuchi A. Increased serum levels of sFlt-1/PlGF ratio in preeclamptic women with onset at <32 weeks compared with ≥32 weeks. Pregnancy Hypertens. 2018 Apr;12:96-103.
[18]Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206(1):58.e1-58.e588.
[19]Boriboonhirunsarn D, Pradyachaipimol A, Viriyapak B. Incidence of superimposed preeclampsia among pregnant Asian women with chronic hypertension. Hypertens Pregnancy. 2017;36(2):226-231.
[20]Verlohren,S;Dröge,LA;The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. Am J Obstet Gynecol.2020 Sep 28.